TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival.
LUAD
LUSC
TP53
immune signatures
lung cancer
sex disparity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Jun 2020
11 Jun 2020
Historique:
received:
03
05
2020
revised:
02
06
2020
accepted:
04
06
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Lung cancer poses the greatest cancer-related death risk and males have poorer outcomes than females, for unknown reasons. Patient sex is not a biological variable considered in lung cancer standard of care. Correlating patient genetics with outcomes is predicted to open avenues for improved management. Using a bioinformatics approach across non-small cell lung cancer (NSCLC) subtypes, we identified where patient sex, mutation of the major tumor suppressor gene, Tumour protein P53 (TP53), and immune signatures stratified outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), among datasets of The Cancer Genome Atlas (TCGA). We exposed sex and TP53 gene mutations as prognostic for LUAD survival. Longest survival in LUAD occurred among females with wild-type (wt) TP53 genes, high levels of immune infiltration and enrichment for pathway signatures of Interferon Gamma (INF-γ), Tumour Necrosis Factor (TNF) and macrophages-monocytes. In contrast, poor survival in men with LUAD and wt TP53 genes corresponded with enrichment of Transforming Growth Factor Beta 1 (TGFB1, hereafter TGF-β) and wound healing signatures. In LUAD with wt TP5
Identifiants
pubmed: 32545367
pii: cancers12061535
doi: 10.3390/cancers12061535
pmc: PMC7352604
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Peter MacCallum Foundation and Sister Institution Network Fund (SINF): MD Anderson - Peter Mac
ID : Internal Grants: numbers not applied
Références
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Cancer Commun (Lond). 2019 Jun 3;39(1):30
pubmed: 31159869
Cancer Cell. 2013 May 13;23(5):634-46
pubmed: 23680148
Nat Commun. 2019 Sep 20;10(1):4295
pubmed: 31541153
Ann Oncol. 2002 Jul;13(7):1087-93
pubmed: 12176788
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
PLoS One. 2014 Feb 07;9(2):e88309
pubmed: 24516633
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
BMC Cancer. 2019 Aug 20;19(1):824
pubmed: 31429720
Nat Commun. 2018 Feb 22;9(1):771
pubmed: 29472616
Cancer Cell. 2016 May 9;29(5):711-722
pubmed: 27165743
BMC Cancer. 2019 May 17;19(1):464
pubmed: 31101024
Front Oncol. 2015 Dec 17;5:284
pubmed: 26734569
Nat Med. 2019 Jun;25(6):954-961
pubmed: 31110349
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Front Immunol. 2019 Jul 03;10:1462
pubmed: 31333642
Clin Lung Cancer. 2018 Nov;19(6):e933-e944
pubmed: 30206043
Trends Genet. 2019 Jul;35(7):478-488
pubmed: 31200807
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Cancer Res. 1992 Feb 1;52(3):734-6
pubmed: 1310070
Nature. 2019 Sep;573(7775):546-552
pubmed: 31461748
Sci Rep. 2019 Aug 12;9(1):11617
pubmed: 31406179
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643228
Oncoimmunology. 2017 Jan 31;6(4):e1285990
pubmed: 28507791
Int J Mol Sci. 2020 Jan 15;21(2):
pubmed: 31952115
BMC Cancer. 2010 Nov 04;10:604
pubmed: 21050467
Curr Oncol. 2018 Jun;25(Suppl 1):S45-S58
pubmed: 29910647
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
J Natl Cancer Inst. 2015 Nov 17;108(1):
pubmed: 26577528
Breast Cancer Res Treat. 2009 Jul;116(1):69-77
pubmed: 18592372
J Natl Cancer Inst. 2017 Dec 1;109(12):
pubmed: 28525914
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
J Immunother Cancer. 2019 Mar 28;7(1):86
pubmed: 30922393
J Thorac Cardiovasc Surg. 2000 Jan;119(1):21-6
pubmed: 10612756
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Cell Biochem. 2019 Mar;120(3):2756-2765
pubmed: 30270458
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Lung Cancer. 2009 Nov;66(2):262-7
pubmed: 19299032
Ann Transl Med. 2018 Mar;6(5):95
pubmed: 29666818
Nat Commun. 2019 Nov 26;10(1):5385
pubmed: 31772231
Hum Mutat. 2015 Apr;36(4):E2423-9
pubmed: 25703262
Nat Rev Immunol. 2016 Dec;16(12):741-750
pubmed: 27667712
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
J Immunol. 2018 Aug 1;201(3):825-826
pubmed: 30038034
Ann Thorac Surg. 2004 Jul;78(1):209-15; discussion 215
pubmed: 15223430
Mol Cancer Res. 2019 Jan;17(1):3-9
pubmed: 30224539
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Commun. 2013;4:2612
pubmed: 24113773
Clin Cancer Res. 2019 Apr 15;25(8):2392-2402
pubmed: 30463850
J Immunother Cancer. 2017 Oct 17;5(1):79
pubmed: 29037250
Clin Cancer Res. 2009 Feb 1;15(3):778-87
pubmed: 19188147
Int J Mol Sci. 2016 Nov 19;17(11):
pubmed: 27869779
Int J Mol Sci. 2020 May 13;21(10):
pubmed: 32414156
PLoS Biol. 2004 Feb;2(2):E7
pubmed: 14737219
Front Immunol. 2019 May 24;10:1084
pubmed: 31178859
Cancer Med. 2018 Sep;7(9):4509-4516
pubmed: 30039553
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711